<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046172</url>
  </required_header>
  <id_info>
    <org_study_id>123436</org_study_id>
    <nct_id>NCT04046172</nct_id>
  </id_info>
  <brief_title>Treatment of Periodontal Disease in Systemic Lupus Erythematosus</brief_title>
  <official_title>Treatment of Periodontal Disease in Systemic Lupus Erytematosus: A Pilot Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to:&#xD;
&#xD;
      Part 1 - Baseline Comparisons&#xD;
&#xD;
      The primary objective of Part 1 is to:&#xD;
&#xD;
      Investigate the association between SLE and a measures of vascular health (brachial artery&#xD;
      flow-mediated dilatyation) in patients with Systemic Lupus Erythematosus (SLE) and a healthy&#xD;
      periodontium compared to patients with SLE and Periodontitis (PD)&#xD;
&#xD;
      Part 2 - Pilot Randomized Clinical Trial To assess the effect of Periodontal Treatment (PT)&#xD;
      on the endothelial function in a population of patients suffering from SLE and PD.&#xD;
&#xD;
      Secondary Secondary objectives include:&#xD;
&#xD;
      Part 1 - Baseline Comparisons&#xD;
&#xD;
      The secondary objectives of Part 1 are to investigate the association of:&#xD;
&#xD;
        -  Inflammatory biomarkers in saliva and blood and periodontal status in patients with SLE&#xD;
           and PD and those with SLE and a healthy periodontium&#xD;
&#xD;
        -  The oral microbiome using plaque analysis and periodontal status in patients with SLE&#xD;
           and PD and those with SLE and a healthy periodontium Part ParPa Part 2 - Pilot&#xD;
           Randomized Controlled Trial Evaluate the effect of PT on biomarkers of SLE disease&#xD;
           severity/progression in a population of patients suffering from SLE and PD.&#xD;
&#xD;
      Evaluate the effect of PT on the B cell panel in a population of patients suffering from SLE&#xD;
      and PD.&#xD;
&#xD;
      Evaluate effect of PT on the systemic inflammatory and oxidative profile of a population of&#xD;
      patients suffering from SLE and PD.&#xD;
&#xD;
      Evaluate effect of PT on skin lesions in a population of patients suffering from SLE and PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoints of this study are in two parts. One part is to quantify the vascular&#xD;
      health in response to PD as a static point prior to active therapy compared to participants&#xD;
      with SLE and healthy perdiodontium . The second part is to quantify and compare the clinical&#xD;
      and systemic outcomes of cases with SLE and PD following periodontalal treamtment.&#xD;
&#xD;
      Part 1 Comparative analyses between cases (SLE with PD) and controls (SLE without PD) will be&#xD;
      performed using ANOVA analysis. Primary outcome will be the difference in flow -mediated&#xD;
      dilatation between groups. Multivariate analysis will be performed to adjust for a number of&#xD;
      covariates including: age, gender, body mass index, ethnicity and supragingival plaque&#xD;
      levels.&#xD;
&#xD;
      All secondary endpoints will be analysed with ANOVA. Pre-specified analyses of secondary&#xD;
      outcomes will include descriptive analyses and differences.&#xD;
&#xD;
      Part 2 Primary clinical periodontal outcome will be the difference in mean flow mediated&#xD;
      (peri-implant) at 6 months between study groups and analysed by analysis of co-variance&#xD;
      model. Age, gender, body mass index, smoking status, ethnicity and dental plaque levels will&#xD;
      be included as additional covariates. Pair-wise comparison and between groups differences&#xD;
      will be calculated using Tukey HSD corrections. If the normality assumption does not seem&#xD;
      reasonable even after transformation of original values, equivalent nonparametric methods&#xD;
      will be used.&#xD;
&#xD;
      Primary systemic inflammatory outcome will be&#xD;
&#xD;
      Changes in FMD (primary outcome), circulating inflammatory, vascular and oxidative biomarkers&#xD;
      (secondary outcomes) will be analysed with analysis of variance for repeated measures using a&#xD;
      conservative F-test (Greenhouse-Geisser correction). If a treatment by time interaction will&#xD;
      be found, pair-wise comparisons will be performed (Bonferroni-Holm adjustment). Side effects&#xD;
      and safety data will be summarized using standard descriptive statistics. Significance will&#xD;
      be set to be at p &lt; 0.05.&#xD;
&#xD;
      Experimental Design&#xD;
&#xD;
      Participants will be approached by the members of healthcare research team explaining the&#xD;
      possibilities to be included in the project. There will be limit in time (24 Hours) to decide&#xD;
      whether participate, subject to the recruitment completion.. A sufficient number of&#xD;
      participants meeting the necessary inclusion/exclusion criteria will be accepted for the&#xD;
      study in order to recruit 30 patients suffering from SLE and PD. Participants who consent to&#xD;
      this study will undergo a baseline visit (Sample size 200) in which they will have a&#xD;
      comprehensive full mouth periodontal probing depths assessment. In addition, full mouth&#xD;
      plaque and gingival bleeding scores will also be calculated. A series of parameters will be&#xD;
      recorded (including age, gender, ethnicity, and body mass index). Saliva samples (1 ml) and&#xD;
      Blood samples (32 ml) will also be collected for analysis of peripheral blood inflammatory&#xD;
      and oxidative biomarkers. Blood cell counts, C-reactive protein, complement levels, dsDNA&#xD;
      autoantibodies, kidney and liver function tests will also be performed. The vascular function&#xD;
      will be assessed by means of an ultrasound scan. After randomization (selected 30 patients)&#xD;
      to either Test or Control Group, the test group will undergo periodontal treatment in 2&#xD;
      sessions within a week from each other. Radiographic examination Orthopentomogram (OPG) will&#xD;
      be taken at the second visit of patient's visit only. Optical coherence tomography will be&#xD;
      done on the patients in vist (2,4 and 6). At 2 months both groups will be reassessed, and the&#xD;
      same information and samples taken at baseline will be collected. The test group will undergo&#xD;
      additional periodontal treatment visit (3) of Intensive periodontal treatment/IPT) within 3&#xD;
      weeks from the 2 months visit. After this visit the Control group will receive the same&#xD;
      periodontal treatment (Control periodontal treatment/CPT). At 6 months both groups will be&#xD;
      seen for the final study assessment. If at any of the study assessment (2 months and 6&#xD;
      months) participants in the control group show signs of progression of PD they will be&#xD;
      treated separately and exited from the trial. After 6 months all the participants will have&#xD;
      treatment irrespective of groups, if they require treatment it will provided&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Total 200 Participants for part 1 (baseline). Randomization (Part 2) Control Test group (n=15) control group (n=15)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>It is a single-blinded study in which cardio-vascular technician will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the effect of periodontal treatment on SLE patients</measure>
    <time_frame>2 years</time_frame>
    <description>Endothelial function/dysfunction (vessel wall elasticity) will be observed in the population of SLE patients (30) who will undergo periodontal treatment (before and after) by using Flow mediated dilatation (FMD) which is an ultra-sound scan of brachial artery in visit 2, 4 and 6).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the effect of PT on biomarkers of SLE disease severity/progression in a population of patients suffering from SLE and PD.</measure>
    <time_frame>2 years</time_frame>
    <description>30 Patients will be recruited and will run a blood test in visit 2, 4 and 6 to observe the CRP (C-reactive Protein) that is an inflammatory marker before and after Periodontal treatment in patients with SLE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effect of Periodontal Treatment on the B-cell panel in a population of patients suffering from SLE and PD.</measure>
    <time_frame>2 Years</time_frame>
    <description>Since B-cells (lymphocytes) are already unnaturally high in SLE patients we want to see if Periodontal Treatment decreases the total cell load/population by Flow cytometry with the blood samples taken form the (30) SLE patients in visit 2, 4 and 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effect of Periodontal Treatment on the systemic inflammatory and oxidative profile of a population of patients suffering from SLE and PD.</measure>
    <time_frame>2 years</time_frame>
    <description>Because SLE and Periodontal diseases are both chronic inflammatory diseases Nitrous oxide production is raised in both diseases leading to self inflicted tissue damage. Blood will be drawn form the (30) patients with SLE and will run a D-ROM test on the blood samples taken in visit 2, 4 and 6 to observe the oxidative profile of the patients with SLE before and after periodontal treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effect of Periodontal Treatment on skin lesions in a population of patients suffering from SLE and PD.</measure>
    <time_frame>2 years</time_frame>
    <description>30 SLE patients will undergo OCT (Optical coherence tomography) investigation. SLE patients might have skin lesion as an immune destructive response by the cells. OCT will observe the skin lesions caused by the disease (SLE) in visit 2, 4 and 6 (before and after periodontal treatment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intensive periodontal treatment (IPT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Control periodontal treatment (CPT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>supra/sub gingival root surface debridement</intervention_name>
    <description>The test group will undergo Intensive periodontal treatment (IPT)</description>
    <arm_group_label>test group</arm_group_label>
    <other_name>IPT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>supra-gingival scaling and polishing</intervention_name>
    <description>Control group will receive the Control periodontal treatment (CPT).</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>CPT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/Female Subject must be 18 years of age or over.&#xD;
&#xD;
          2. Patients with 4 or more criteria for juvenile systemic lupus erythematosus (JSLE) or&#xD;
             SLE according to the American College of Rheumatology (ACR) 1997 criteria or SLICC&#xD;
             2012 criteria or biopsy proven lupus nephritis with one additional supportive test on&#xD;
             at least two occasions (positive Anti-nuclear antibodies (ANA), anti-dsDNA antibodies&#xD;
             or anti-Sm antibodies).&#xD;
&#xD;
          3. Presence of moderate to severe periodontitis (at least 30 pockets with Probing depth&#xD;
             equal or greater than 5mm).&#xD;
&#xD;
          4. Subject must have voluntarily signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breastfeeding.&#xD;
&#xD;
          2. Having fewer than 15 teeth.&#xD;
&#xD;
          3. Subject knowingly has HIV or Hepatitis.&#xD;
&#xD;
          4. Subject is not capable to give informed consent.&#xD;
&#xD;
          5. Presence of concomitant rheumatoid arthritis, Sjogren syndrome, diabetes mellitus.&#xD;
&#xD;
          6. Smoking.&#xD;
&#xD;
          7. Subject on anticoagulants.&#xD;
&#xD;
          8. Subjects on chronic antibiotic therapy or who require antibiotic coverage for&#xD;
             periodontal procedures.&#xD;
&#xD;
          9. Subjects who received periodontal treatment within 6 months from the baseline&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco D'Aiuto, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Periodontology Eastman Dental Institute,UCL.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Coziana Ciurtin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Rheumatology, UCLH.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Orlandi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Periodontology Eastman Dental Institute,UCL.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacopo Buti, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Periodontology Eastman Dental Institute,UCL.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Syed Basit Hussain, BDS</last_name>
    <phone>+447477024924</phone>
    <email>syed.hussain.16@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastman clinical investigation centre (ECIC) Eastman Dental Institute.</name>
      <address>
        <city>London</city>
        <zip>wc1 x8ld</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, Tarp U, Poulsen LH, van Overeem Hansen G, Skaarup B, Hansen TM, Pødenphant J, Halberg P. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol. 1998;17(6):478-84.</citation>
    <PMID>9890675</PMID>
  </reference>
  <reference>
    <citation>Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, Greenlee RT. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014 Apr;41(4):680-7. doi: 10.3899/jrheum.130874. Epub 2014 Feb 15.</citation>
    <PMID>24532834</PMID>
  </reference>
  <reference>
    <citation>Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 Feb;60(2):221-5.</citation>
    <PMID>1251849</PMID>
  </reference>
  <reference>
    <citation>Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejía JC, Aydintug AO, Chwalinska-Sadowska H, de Ramón E, Fernández-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep;82(5):299-308.</citation>
    <PMID>14530779</PMID>
  </reference>
  <reference>
    <citation>Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, Atzeni F, Piccoli A, Todesco S. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006 Aug;119(8):700-6.</citation>
    <PMID>16887417</PMID>
  </reference>
  <reference>
    <citation>Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.</citation>
    <PMID>9048514</PMID>
  </reference>
  <reference>
    <citation>Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol. 2010 Feb 1;5(1):75-100.</citation>
    <PMID>20305727</PMID>
  </reference>
  <reference>
    <citation>Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000 May;26(2):257-78. Review.</citation>
    <PMID>10768212</PMID>
  </reference>
  <reference>
    <citation>Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol. 2001 Sep;13(5):341-4. Review.</citation>
    <PMID>11604586</PMID>
  </reference>
  <reference>
    <citation>Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 Dec 18;349(25):2407-15.</citation>
    <PMID>14681506</PMID>
  </reference>
  <reference>
    <citation>Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, Gilburd B, Corbanese S, Patnaik M, Zampieri S, Peter JB, Favaretto E, Iaccarino L, Sherer Y, Todesco S, Pauletto P. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003 Nov;62(11):1071-7.</citation>
    <PMID>14583570</PMID>
  </reference>
  <reference>
    <citation>Korkmaz H, Onalan O. Evaluation of endothelial dysfunction: flow-mediated dilation. Endothelium. 2008 Jul-Aug;15(4):157-63. doi: 10.1080/10623320802228872. Review.</citation>
    <PMID>18663619</PMID>
  </reference>
  <reference>
    <citation>Inoue T, Node K. Vascular failure: A new clinical entity for vascular disease. J Hypertens. 2006 Nov;24(11):2121-30. Review.</citation>
    <PMID>17053528</PMID>
  </reference>
  <reference>
    <citation>Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002 Aug 6;106(6):653-8.</citation>
    <PMID>12163423</PMID>
  </reference>
  <reference>
    <citation>Matsuzawa Y, Lerman A. Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment. Coron Artery Dis. 2014 Dec;25(8):713-24. doi: 10.1097/MCA.0000000000000178. Review.</citation>
    <PMID>25365643</PMID>
  </reference>
  <reference>
    <citation>Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991 Apr;68(4):1027-34.</citation>
    <PMID>2009605</PMID>
  </reference>
  <reference>
    <citation>Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997 Jan-Feb;39(4):287-324. Review.</citation>
    <PMID>9050817</PMID>
  </reference>
  <reference>
    <citation>Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5.</citation>
    <PMID>1359209</PMID>
  </reference>
  <reference>
    <citation>Piper MK, Raza K, Nuttall SL, Stevens R, Toescu V, Heaton S, Gardner-Medwin J, Hiller L, Martin U, Townend J, Bacon PA, Gordon C. Impaired endothelial function in systemic lupus erythematosus. Lupus. 2007;16(2):84-8.</citation>
    <PMID>17402363</PMID>
  </reference>
  <reference>
    <citation>Mak A, Kow NY, Schwarz H, Gong L, Tay SH, Ling LH. Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression. Sci Rep. 2017 Aug 4;7(1):7320. doi: 10.1038/s41598-017-07574-1.</citation>
    <PMID>28779080</PMID>
  </reference>
  <reference>
    <citation>Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009 Dec 1;54(23):2129-38. doi: 10.1016/j.jacc.2009.09.009. Review.</citation>
    <PMID>19942084</PMID>
  </reference>
  <reference>
    <citation>Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, Ndiaye C. The global burden of oral diseases and risks to oral health. Bull World Health Organ. 2005 Sep;83(9):661-9. Epub 2005 Sep 30.</citation>
    <PMID>16211157</PMID>
  </reference>
  <reference>
    <citation>Albandar JM, Rams TE. Global epidemiology of periodontal diseases: an overview. Periodontol 2000. 2002;29:7-10.</citation>
    <PMID>12102700</PMID>
  </reference>
  <reference>
    <citation>D'Aiuto F, Graziani F, Tetè S, Gabriele M, Tonetti MS. Periodontitis: from local infection to systemic diseases. Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3 Suppl):1-11. Review.</citation>
    <PMID>16848982</PMID>
  </reference>
  <reference>
    <citation>Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol. 2001 Sep;72(9):1221-7.</citation>
    <PMID>11577954</PMID>
  </reference>
  <reference>
    <citation>D'Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J Periodontol. 2013 Apr;84(4 Suppl):S85-S105. doi: 10.1902/jop.2013.134007. Review.</citation>
    <PMID>23631587</PMID>
  </reference>
  <reference>
    <citation>Orlandi M, Suvan J, Petrie A, Donos N, Masi S, Hingorani A, Deanfield J, D'Aiuto F. Association between periodontal disease and its treatment, flow-mediated dilatation and carotid intima-media thickness: a systematic review and meta-analysis. Atherosclerosis. 2014 Sep;236(1):39-46. doi: 10.1016/j.atherosclerosis.2014.06.002. Epub 2014 Jun 17. Review.</citation>
    <PMID>25014033</PMID>
  </reference>
  <reference>
    <citation>D'Aiuto F, Nibali L, Parkar M, Patel K, Suvan J, Donos N. Oxidative stress, systemic inflammation, and severe periodontitis. J Dent Res. 2010 Nov;89(11):1241-6. doi: 10.1177/0022034510375830. Epub 2010 Aug 25.</citation>
    <PMID>20739696</PMID>
  </reference>
  <reference>
    <citation>Tonetti MS, D'Aiuto F, Nibali L, Donald A, Storry C, Parkar M, Suvan J, Hingorani AD, Vallance P, Deanfield J. Treatment of periodontitis and endothelial function. N Engl J Med. 2007 Mar 1;356(9):911-20. Erratum in: N Engl J Med. 2018 Jun 13;:null.</citation>
    <PMID>17329698</PMID>
  </reference>
  <reference>
    <citation>de Pablo P, Dietrich T, McAlindon TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol. 2008 Jan;35(1):70-6. Epub 2007 Nov 15.</citation>
    <PMID>18050377</PMID>
  </reference>
  <reference>
    <citation>Calderaro DC, Ferreira GA, de Mendonça SM, Corrêa JD, Santos FX, Sanção JG, da Silva TA, Teixeira AL. Is there an association between systemic lupus erythematosus and periodontal disease? Rev Bras Reumatol Engl Ed. 2016 May-Jun;56(3):280-4. doi: 10.1016/j.rbre.2015.08.003. Epub 2015 Sep 8. English, Portuguese.</citation>
    <PMID>27267648</PMID>
  </reference>
  <reference>
    <citation>Rutter-Locher Z, Smith TO, Giles I, Sofat N. Association between Systemic Lupus Erythematosus and Periodontitis: A Systematic Review and Meta-analysis. Front Immunol. 2017 Oct 17;8:1295. doi: 10.3389/fimmu.2017.01295. eCollection 2017.</citation>
    <PMID>29089946</PMID>
  </reference>
  <reference>
    <citation>Rydén L, Buhlin K, Ekstrand E, de Faire U, Gustafsson A, Holmer J, Kjellström B, Lindahl B, Norhammar A, Nygren Å, Näsman P, Rathnayake N, Svenungsson E, Klinge B. Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study. Circulation. 2016 Feb 9;133(6):576-83. doi: 10.1161/CIRCULATIONAHA.115.020324. Epub 2016 Jan 13.</citation>
    <PMID>26762521</PMID>
  </reference>
  <reference>
    <citation>Fabbri C, Fuller R, Bonfá E, Guedes LK, D'Alleva PS, Borba EF. Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy. Clin Rheumatol. 2014 Apr;33(4):505-9. doi: 10.1007/s10067-013-2473-2. Epub 2014 Jan 11.</citation>
    <PMID>24415114</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Periodontitis</keyword>
  <keyword>SLE</keyword>
  <keyword>Lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

